Oragene

Oragenics Issues Update to Shareholders

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, FDA, Health, Other Health, Pharmaceutical, Other Science, Research, Managed Care, Infectious Diseases, General Health, Science, COVID-19, Clinical Trials, Medical Supplies, Niemann–Pick disease, type C, Oragene, Optimism, Acquisition, Common stock, Growth, Concussion, Internet, Administration, Series, Pharmaceutical industry, Security (finance), Odyssey

On October 5, 2023, we proudly announced that we had entered into an agreement to acquire Odyssey Health, Inc.’s lead assets.

Key Points: 
  • On October 5, 2023, we proudly announced that we had entered into an agreement to acquire Odyssey Health, Inc.’s lead assets.
  • The assets are related to Odyssey’s proprietary neurological drug therapies, including their proprietary formulation and nasal delivery system.
  • We understand concerns about potential dilution and its impact on shareholders.
  • Thank you for your continued support of Oragenics.

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Retrieved on: 
Wednesday, October 18, 2023
Health, Infectious Diseases, Health Technology, COVID-19, General Health, Pharmaceutical, Biotechnology, Odyssey, Sale, Bradenton, Florida, NYSE, Therapy, Compensated emancipation, Financial management, Cassidy, Rutgers University, Professional Football Compensation Committee, Bachelor of Arts, Business administration, ECOR, CFO, Patient, Audit committee, Management, Oragene

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023.
  • “We are delighted to welcome Bruce Cassidy and John Gandolfo to the Oragenics Board,” said Charlie Pope, Chairman of Oragenics.
  • I look forward to working with the Oragenics Board and the Odyssey team to help steer the new strategy and direction of the Company,” said Bruce Cassidy.
  • I am happy to continue my involvement as a member of Oragenics Board,” said John Gandolfo.

Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Retrieved on: 
Thursday, October 5, 2023
Biotechnology, General Health, Mental Health, Health, Pharmaceutical, OTCQB, Sport, NYSE, Concussion, Anxiety, Series, Inflammation, Brain, Trial of the century, Therapy, Animal, NPC, Safety, Memory, FDA, Science, Niemann–Pick disease, type C, Human, Oxidative stress, Pharmaceutical industry, Oragene, Odyssey

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Odyssey Health, Inc. (OTCQB: ODYY ) (“Odyssey”) announce the signing of a definitive agreement under which Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Odyssey Health, Inc. (OTCQB: ODYY ) (“Odyssey”) announce the signing of a definitive agreement under which Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies.
  • The asset purchase includes cash payments to Odyssey totaling $1.0 million and eight (8) million shares of Oragenics’ Series F Convertible Preferred Stock.
  • After closing this transaction, certain members of Odyssey management intend to join Oragenics and lead the continued development of Odyssey’s pipeline of neurological drug therapies and technologies.
  • “Our lead drug candidate for treating concussion has performed well in preclinical studies, generating promising efficacy and safety data in animal models.

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Retrieved on: 
Friday, September 29, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Dental, Lantern, Tooth decay, Partnership, Radioactive decay, NYSE, Pharmaceutical industry, Oragene

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a materials transfer agreement.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a materials transfer agreement.
  • Under this agreement, Oragenics has received a cash payment of $50,000 alongside an enticing opportunity to acquire one million shares of Lantern Bioworks’ equity.
  • Additionally, Lantern Bioworks has committed to pay Oragenics a ten percent (10%) royalty on the net income generated from any products stemming from the transferred assets.
  • Crucially, this agreement does not entail the transfer of intellectual property ownership from Oragenics to Lantern Bioworks.

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Retrieved on: 
Monday, June 5, 2023
COVID-19, Research, Infectious Diseases, Health Technology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Antigen, SARS-CoV-2, NRC, CHO, Infection, Transport, Immunization, NYSE, National Research Council, Vaccine, Oragene

The project, which aims to build upon Oragenics’ current lead intranasal vaccine candidate NT-CoV2-1, is a collaboration with the National Research Council of Canada (NRC) and Inspirevax.

Key Points: 
  • The project, which aims to build upon Oragenics’ current lead intranasal vaccine candidate NT-CoV2-1, is a collaboration with the National Research Council of Canada (NRC) and Inspirevax.
  • The grant awarded by CQDM is expected to help Oragenics fund the development of two to four well-characterized stable CHO pools expressing new, cross-protective vaccine antigens with well-established preclinical efficacy using intranasal immunization.
  • The grant funding is awarded through SynergiQC, a Quebec-based funding program for biopharmaceutical research created by CQDM.
  • CQDM extends its funding capacity to the development of biopharmaceutical products with high industrial and commercial value, such as more competitive molecules and other technologies.

Oragenics to Participate in the World Vaccine Congress Washington

Retrieved on: 
Wednesday, March 29, 2023
Health, Infectious Diseases, Genetics, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, GLP, Human, SARS-CoV-2, Toxicity, Infection, Immunoglobulin A, Antibody, Patient, Blood, Immunoglobulin G, Scientific Reports, Toxicology, Rabbit, Mouse, Viral load, NYSE, Safety, Pharmaceutical industry, Vaccine, Nature, Oragene, D.C

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that Kim Murphy, Chief Executive Officer, will be participating in the World Vaccine Congress Washington, being held April 3-6, 2023, in Washington, D.C.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that Kim Murphy, Chief Executive Officer, will be participating in the World Vaccine Congress Washington, being held April 3-6, 2023, in Washington, D.C.
    Ms. Murphy will be holding meetings to highlight the company’s lead COVID-19 intranasal vaccine candidate, NT-CoV2-1, and to explore partnering opportunities.
  • Oragenics believes an intranasal COVID-19 vaccine holds several potential benefits compared with injectable vaccines, including targeting mucosal immunity, reducing transmission and offering a needle-free alternative for patients.
  • “I am excited to take part in the World Vaccine Congress this year and share our progress toward a highly differentiated intranasal COVID-19 vaccine,” said Ms. Murphy.
  • Earlier this month Oragenics entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301.

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Methicillin-resistant Staphylococcus aureus, NYSE, Infection, VRE, Daptomycin, Phenotype, Enterococcus-1 RNA motif, Methicillin, MRSA, Vancomycin, Oxacillin, Vaccine, Antibiotics, Oragene

Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.

Key Points: 
  • Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.
  • Oragenics’ lantibiotics platform is focused on the development of new antibiotics effective against certain pathogens including vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA).
  • Oragenics is focused on addressing this unmet medical need through its novel lantibiotics platform, and the results of its work with Linnaeus Bioscience advance Oragenics’ long-term mission to become a provider of effective treatments for infectious diseases.
  • Oragenics remains committed to fighting infectious diseases through the development of its lantibiotics pipeline against MRSA and VRE pathogens.

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

Retrieved on: 
Wednesday, March 8, 2023
Biotechnology, Infectious Diseases, COVID-19, Health, Pharmaceutical, University, Pharmacy, NYSE, Rehabilitation, HEALTH, Assistant Secretary of the Treasury for Management, Infection, Nursing, CFO, BYU College of Family, Home and Social Sciences, Management, Oragene

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023.
  • Ms. Huffman is a seasoned financial executive with more than a dozen years of leadership experience at publicly traded and private healthcare companies.
  • In 2019, Ms. Huffman was a founding member of Banyan Pediatric Care Centers and served as its Chief Financial Officer.
  • Prior to Arboreta Healthcare, Ms. Huffman was the Chief Financial Officer for Signature HomeNow, a home healthcare services company.

Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

Retrieved on: 
Wednesday, March 1, 2023
Biotechnology, Pharmaceutical, Health, COVID-19, Safety, Good laboratory practice, Immunoglobulin G, NYSE, Immunoglobulin A, Patient, Trial of the century, JDC, Rabbit, Bangladesh Technical Education Board, Infection, Vaccine, Viral load, Pharmaceutical industry, Oragene

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301, for the development of NT-CoV2-1, Oragenics’ lead intranasal COVID-19 vaccine candidate.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301, for the development of NT-CoV2-1, Oragenics’ lead intranasal COVID-19 vaccine candidate.
  • Under the exclusive licensing agreement, Oragenics will pursue the development of NT-CoV2-1 with Inspirevax’s novel BDX301 intranasal mucosal adjuvant.
  • Additionally, the agreement provides a certain period of time for the companies to expand their collaboration to pursue the development of additional intranasal vaccine candidates using Inspirevax’s adjuvants.
  • We are excited to collaborate with the experts at Inspirevax to pursue the development of novel intranasal vaccine candidates,” explains Kimberly Murphy, President and Chief Executive Officer of Oragenics.

Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate

Retrieved on: 
Thursday, December 22, 2022
Pharmaceutical, Health, COVID-19, Blood, Mouse, Immunoglobulin A, GLP, COVID-19, Toxicity, Viral load, Scientific Reports, NYSE, Infection, Severe acute respiratory syndrome coronavirus 2, Safety, Rabbit, Antibody, Human, Immunoglobulin G, Good laboratory practice, Pharmaceutical industry, Vaccine, Oragene, Nature

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, today announced results indicating no toxicity signals or adverse events from its Good Laboratory Practices (GLP) toxicology study in rabbits evaluating the safety and immunogenicity of its NT-CoV2-1 intranasal vaccine candidate.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, today announced results indicating no toxicity signals or adverse events from its Good Laboratory Practices (GLP) toxicology study in rabbits evaluating the safety and immunogenicity of its NT-CoV2-1 intranasal vaccine candidate.
  • “There is an unmet medical need for an intranasally administered COVID-19 vaccine.
  • We are encouraged by these favorable toxicology study results, which advance the preclinical work required for pursuing regulatory permission to begin human testing.
  • This marks an important milestone in the progress of bringing an intranasal COVID-19 vaccine to the market,” said Kim Murphy, President and Chief Executive Officer of Oragenics.